搜索优化
English
搜索
Copilot
图片
视频
地图
资讯
购物
更多
航班
旅游
酒店
房地产
笔记本
Top stories
Sports
U.S.
Local
World
Science
Technology
Entertainment
Business
More
Politics
时间不限
过去 1 小时
过去 24 小时
过去 7 天
过去 30 天
按相关度排序
按时间排序
The Pharma Letter
38 分钟
Insilico’s IPF data an early indicator of AI potential
Sino-American firm Insilico Medicine has shown the potential not just of its pipeline and lead candidate by presenting ...
The Pharma Letter
2 小时
Sunshine calls on Apollo for work on novel bi-specific
Apollo Therapeutics and Sunshine Lake Pharma have signed a license deal for APL-18881, a bi-specific fusion protein targeting ...
The Pharma Letter
2 小时
BioNTech to boost oncology offering with buy of Biotheus
Although it is seeing a downturn in sales and profits, German biotech BioNTech (Nasdaq: BNTX) is continuing to acquire assets ...
The Pharma Letter
17 小时
Argenx and Zai Lab secure China approval for Vyvgart Hytrulo
Dutch firm Argenx Euronext: ARGX) and China’s Zai Lab (HKEX: 9688) have received an approval from the National Medical ...
The Pharma Letter
17 小时
UK looks again at Sarclisa for myeloma as demand grows
Sanofi (Euronext: SAN) has announced that the UK's health technology assessor will conduct a new review of its Sarclisa ...
The Pharma Letter
4 小时
GSK inks multi-target alliance with Versalius
Cambridge, USA-based Vesalius Therapeutics has entered into a multi-target strategic alliance with the UK’s GSK to discover ...
The Pharma Letter
3 小时
Schrödinger announces collaboration with Novartis
Physics-based US software specialist Schrödinger’s shares leapt nearly 14% to $22.25 on the back of news that it has entered ...
The Pharma Letter
4 小时
Roche powers Flare’s tilt at cancer
Privately-held Flare Therapeutics, a US biotech targeting transcription factors to discover precision medicines for oncology ...
The Pharma Letter
5 小时
Lundbeck reports 18% revenue growth in third quarter
Lundbeck’s Q3 2024 revenue rose 18% to $815 million, driven by strategic brands like Vyepti and Rexulti in the USA. Vyepti’s ...
The Pharma Letter
17 小时
BeiGene posts strong 3rd-qtr 2024 sales growth
Sino-American oncology company BeiGene (Nasdaq: BGNE) has announced third-quarter 2024 financials, showing the total revenues ...
The Pharma Letter
17 小时
Syndax shares slide despite pivotal trial success
Syndax Pharmaceuticals (Nasdaq: SNDX) has announced that its Phase II AUGMENT-101 trial of experimental drug revumenib ...
The Pharma Letter
22 小时
FDA slaps CRL on Ocaliva sNDA
Intercept Pharmaceuticals, now wholly owned subsidiary of Italy’s Alfasigma, today revealed that the US Food and Drug ...
一些您可能无法访问的结果已被隐去。
显示无法访问的结果
反馈